Clinical Trial 22179

• Overview

  Study Title:

  Determinants of Cancer Survivorship Among People Living with HIV (HIV/AIDS/AGING/CANCER)

  Summary:

  The aims of this study are: 1. Estimate differences and identify determinants (clinical, behavioral, and social) of cancer survival among non-AIDS defining cancer survivors living with and without HIV. 2. Evaluate longitudinal changes in individual-level clinical (e.g., comorbidities), physical (e.g., frailty, activities of daily living), and psychosocial (e.g., depression, quality of life) outcomes after a non-AIDS defining cancer diagnosis and whether these changes differ by HIV status.

  Objective:

  Aim 1: Estimate differences and identify determinants (clinical, behavioral, and social) of cancer survival among non-AIDS defining cancer survivors living with and without HIV. Using MWCCS data, we will examine survival differences by HIV infection for all non-AIDS defining cancers (as of 3/31/2020, n=836), and by site, anal (n=56), breast (n=79), colorectal (n=59), lung and bronchus (n=117), and prostate (n=113) cancers. Clinical, social, and behavioral measures collected at time of cancer diagnosis up to the most recent MWCCS study visit will be used. Aim 2: Evaluate longitudinal changes in individual-level clinical (e.g., general comorbidities, adherence to ART), physical (e.g., frailty, activities of daily living), and psychosocial (e.g., depression, quality of life) outcomes after a non-AIDS defining cancer diagnosis and whether these changes differ by HIV status. We will leverage longitudinal data collected from the MWCCS. We will focus on all non-AIDS defining cancers together and by site. Clinical, physical, and psychosocial measures collected over time pre- (within one year) and post-cancer diagnosis will be used. Aim 3: Explore the role of patient cancer care quality on cancer survivorship outcomes among people living with and without HIV with a non-AIDS defining cancer diagnosis. We will administer a quantitative survey to cancer patients living with HIV (n=150) and matched HIV-negative cancer patients (n=150) who have at least survived 6 months post their cancer diagnosis. We will take a sequential mixed-methods approach, and apply lessons learned from the quantitative data to carry out focus group (n= 30) interviews of cancer patients living with HIV to further contextualize results.

• Inclusion Criteria

  Inclusion Criteria:
  • Diagnosis of any stage invasive cancer (non-AIDS defining cancer) with a preceding HIV diagnosis.
  • Currently engaged in active cancer treatment (defined as having received any form of treatment within the past 12 months), and was diagnosed at least one month prior.
  • Diagnosed at least one month prior to registration in this study
  • Other criteria may apply

• Exclusion Criteria

  Exclusion Criteria:
  • Documented or observable psychiatric or neurological disorder that would interfere with study participation.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.